Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 8
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
MSI-H / dMMR
gastric cancer · Immune Checkpoint Inhibitor
MSI-H / dMMR is flagged as manual review required because public trials show inclusion required evidence in 11 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 16
Common snippets: MSI-h | MSI-h | MSI-h
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03505320 | https://clinicaltrials.gov/study/NCT05535569 | https://clinicaltrials.gov/study/NCT07223424 | https://clinicaltrials.gov/study/NCT02589496 | https://clinicaltrials.gov/study/NCT03407976 | https://clinicaltrials.gov/study/NCT03894618 | https://clinicaltrials.gov/study/NCT03257163 | https://clinicaltrials.gov/study/NCT07542262 | https://clinicaltrials.gov/study/NCT04006262 | https://clinicaltrials.gov/study/NCT07673887 | https://clinicaltrials.gov/study/NCT06901531